For example, a higher presence of CD8+ cells in TILs before therapy, as well as in the lymphoid infiltrate in the tumor bed after neoadjuvant treatment, is correlated with an increased pathological complete response (pCR) rate (9). The gene discussed is CD8A; the disease is neoplasm.